Media coverage about Onconova Therapeutics (NASDAQ:ONTX) has trended positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Onconova Therapeutics earned a news sentiment score of 0.30 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.059688891708 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Onconova Therapeutics (NASDAQ ONTX) traded down 1.22% during trading on Friday, hitting $1.62. The stock had a trading volume of 30,221 shares. Onconova Therapeutics has a 52 week low of $1.51 and a 52 week high of $3.88. The firm has a 50 day moving average price of $1.93 and a 200-day moving average price of $2.31. The stock’s market capitalization is $15.96 million.

Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.43. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 762.13%. The company had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.25 million. On average, equities research analysts forecast that Onconova Therapeutics will post ($2.92) EPS for the current fiscal year.

A number of equities analysts have recently weighed in on the company. Maxim Group set a $6.00 target price on Onconova Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Dawson James reaffirmed a “buy” rating on shares of Onconova Therapeutics in a research report on Tuesday, July 25th.

COPYRIGHT VIOLATION WARNING: “Positive News Coverage Somewhat Unlikely to Impact Onconova Therapeutics (ONTX) Share Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/27/positive-news-coverage-somewhat-unlikely-to-impact-onconova-therapeutics-ontx-share-price.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Insider Buying and Selling by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Receive News & Stock Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related stocks with our FREE daily email newsletter.